Karyopharm Therapeutics Inc

$ 8.970
Updated 01:00:00
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 1,190,250
High $ 9.400
Low $ 8.910
Open $ 9.320
Prev close $ 9.330
# of shares 60.71M
Market cap 544.55M USD

Market closed
Karyopharm Therapeutics Inc
Market is closed, opens at 14:30
Price development Latest 1 week 1 month 3 months 6 months 1 year
  8.97 -2.6% Stock price decreasing -2.1% Stock price decreasing -13.8% Stock price decreasing -50.9% Stock price decreasing -38.5% Stock price decreasing
Powered by TradingView

News about Karyopharm Therapeutics Inc

  • English
  • Regulatory news
21 Feb
21 Feb
07 Feb
04 Feb
08 Jan
02 Jan
02 Jan
04 Dec
03 Dec
01 Dec

Company profile

Karyopharm Therapeutics Inc., is a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. Karyopharm's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
22 February 2019 13:25:48
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB6 - 2019-02-22 14:25:48 - 2019-02-22 13:25:48 - 1000 - Website: OKAY